Loading...
OTCM
RGBP
Market cap302kUSD
Dec 05, Last price  
0.01USD
1D
6.67%
1Q
-55.35%
Jan 2017
-99.98%
IPO
-100.00%
Name

Regen BioPharma Inc

Chart & Performance

D1W1MN
OTCM:RGBP chart
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
24.38%
Rev. gr., 5y
16.55%
Revenues
237k
0.00%
000192,000100,000110,000100,000110,000110,000171,194235,517236,560236,560
Net income
-668k
L
-401,256-355,034-756,353-11,195,147-7,750,594-5,839,039-4,715,200-4,324,1301,788,602-7,132,0305,489,8671,023,508-668,000
CFO
-693k
L+298.55%
-401,256-284,836-746,891-11,012,283-1,672,245-1,894,419-1,578,039-481,79318,645-1,130,938-606,921-173,917-693,141

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Regen BioPharma, Inc. focuses on the development of regenerative medical applications in the United States. It engages in actively identifying small molecules that inhibit or express NR2F6 leading to immune cell activation for oncology applications, and immune cell suppression for autoimmune disease. The company is in the early stages of development of its products, and therapies. Regen BioPharma, Inc. was incorporated in 2012 and is based in La Mesa, California.
IPO date
Sep 03, 2014
Employees
1
Domiciled in
US
Incorporated in
US

Valuation

Title
in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑092023‑092022‑092021‑092020‑092019‑092018‑092017‑092016‑09
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT